Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S312000, C514S310000, C546S114000, C546S153000
Reexamination Certificate
active
07973050
ABSTRACT:
Novel compounds in enantiomeric excess that are inhibitors of bacterial methionyl synthetase (MetRS) are disclosed. Also disclosed are methods for their preparation and their use in therapy as antibacterial agents, and in particular their use in therapy forClostridium difficileinfection.
REFERENCES:
patent: 4710506 (1987-12-01), Davies et al.
patent: 6943175 (2005-09-01), Berge et al.
patent: 7030137 (2006-04-01), Berge et al.
patent: 7220757 (2007-05-01), Berge et al.
patent: 2008/0146609 (2008-06-01), Guiles et al.
patent: 2008/0227808 (2008-09-01), Guiles et al.
patent: 2009/0163536 (2009-06-01), Guiles et al.
patent: 0785268 (1997-07-01), None
patent: WO 99/55677 (1999-11-01), None
patent: WO 00/21949 (2000-04-01), None
patent: WO 00/71524 (2000-11-01), None
patent: WO 2004/052288 (2004-06-01), None
patent: WO 2004/069196 (2004-08-01), None
patent: WO 2004/078119 (2004-09-01), None
patent: WO 2008/039639 (2008-04-01), None
patent: WO 2008/039640 (2008-04-01), None
patent: WO 2008/039641 (2008-04-01), None
patent: WO 2008/039642 (2008-04-01), None
Kim et al. (Bioorganic & Medicinal Chemistry (2003), 11(24), 5325-5331).
Lin et al. (Principles and Applications of Asymmetric Synthesis, Wiley Interscience, 2001, p. 1-14).
U.S. Appl. No. 11/853,314, filed Sep. 11, 2007, Guiles, et al.
Barlett & Perl,N. Engl.J. Med., 353:2503-2505 (2005).
Clabots et al.,J. Infect. Dis. 166:561-567 (1992).
Fleischmann et al.,Science269:496-512 (1995).
Jarvest,Bioorg. &Med. Chem. Lett. 14 3937-3941 (2004.
McFarland et al.,N. Engl. J. Med. 320:204-210 (1989).
Smith M.B.,March J, March's Advanced Org. Chem., 5th ed., Wiley-Interscience, NY, p. 139-143 (2001).
Barker (1995) “An Easy Synthesis of 3-Amino- and 3-Nitrothiophene” Synthetic Comm 25:3729-3734.
Brown et al (2003) “Horizontal Transfer of Drug-Resistant Aminoacyl-Transfer-RNA Synthesis of Anthrax and Gram-Positive Pathogens” EMBO Reports 4(7):692-698.
Elsayed and Zhang (2004) “Bacteremia Caused byClostrididum symbiosum” J. Clin. Microbiology 42(9):4390-4392.
Hurdle et al (2005) “Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents” Antimicrobial Agents and Chemotherapy 49(12):4821-4833.
Jarvest et al (2003) “Conformational Restriction of Methionyl tRNA Synthetase Inhibitors Leading to Analogues with Potent Inhibition and Excellent Gram-Positive Antibacterial Activity” Bioorganic & Medicinal Chemistry Letters 13:1265-1268.
Jiang et al (2009) “Clostridium glycolicumWound Infections: Case Reports and Review of the Literature” J. Clin. Microbiology 47(5):1599-1601.
King (1994) “Bioisosteres, Conformational Restriction, and Prodrugs—Case History: An Example of a Conformational Restriction Approach” Medicinal Chemistry: Principle and Practice:206-225.
Office Action mailed Nov. 24, 2010 with respect to U.S. Appl. No. 11/853,636.
Office Action mailed Sep. 15, 2010 with respect to U.S. Appl. No. 11/853,314.
Office Action mailed Sep. 15, 2010 with respect to U.S. Appl. No. 11/853,589.
Smith-Slatas et al (Mar. 27, 2006) “Clostridium septicumInfections in Children: A Case Report and Review of the Literature” Pediatrics 117:e796-e805 (http:www.pediatrics.org/cgi/content/full/117/4/e796).
Gentry et al (2003) “Variable Sensitivity to Bacterial Methionyl-tRNA Synthetase inhibitors Reveals Subpopulations ofStreptococcus pneumoniaewith Two Distinct methionyl-tRNA Synthetase Genes” Antimicrobial Agents and Chemotherapy 47(6):1784-1789.
Jarvest et al (2002) “Nanomolar Inhibitors ofStaphylococcus aureusMethionyl tRNA Synthetase with Potent Antibacterial Activity Against Gram-Positive Pathogens” Journal of Medicinal Chemistry 45(10):1959-1962.
EP Supplemental Search Report (Mar. 21, 2011) received in EP Application No. 07842226.8.
Bartlett et al (1978) “Role ofClostridium difficilein Antibiotic-Associated Pseudomembranous colitis” Gastroenterology 75(5):778-782.
Critchley et al (2005) “Antibacterial Activity of REP8839, a New Antibiotic for Topical Use” Antimicrobial Agents and Chemotherapy 49(10):4247-4252.
Hall and O'Toole (1935) “Intestinal Flora in Newborn Infants with Description of a New Pathogenic Anaerobe” American Journal of Diseases of Children 49:390-402.
Loo et al (2005) “A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile-Associated Diarrhea with High Morbidity and Mortality” New England Journal of Medicine 353:2442-2449.
Lyerly et al (1988) “Clostridium difficile: Its Disease and Toxins” Clinical Microbiology Reviews 1(1):1-18.
Pépin et al (2005) “Increasing Risk of Relapse After Treatment ofClostridium difficileColitis in Quebec, Canada” Clin. Infect. Dis. 40:1591-1597.
Teasley et al (1983) “Prospective Randomised Trial of Metronidazole Versus Vancomycin forClostridium-difficile-Associated Diarrhoea and Colitis” The Lancet 2:1043-104.
Thomas et al (2003) “Antibiotics and Hospital-AcquiredClostridium difficile-Associated Diarrhoea: a Systematic Review” Journal of Antimicrobial Chemotherapy 51:1339-135.
Voth and Ballard (2005) “Clostridium-difficileToxins: Mechanism of Action and Role in Disease” Clinical Microbiology Reviews 18(2):247-16.
Wilcox and Spencer (1992) “Clostridium difficileInfection: Responses, Relapses and Re-Infections” Journal of Hospital Infection 22:85-92.
Guiles Joseph
Gyorkos Albert Charles
Janjic Nebojsa
Strong Sarah
Sun Xicheng
Crestone, Inc.
Ramachandran Uma
Swanson & Bratschun L.L.C.
Wang Shengjun
LandOfFree
Enantiomeric compounds with antibacterial activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enantiomeric compounds with antibacterial activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enantiomeric compounds with antibacterial activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688187